<SEC-DOCUMENT>0001193125-21-342891.txt : 20211130
<SEC-HEADER>0001193125-21-342891.hdr.sgml : 20211130
<ACCEPTANCE-DATETIME>20211130071355
ACCESSION NUMBER:		0001193125-21-342891
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211130
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211130
DATE AS OF CHANGE:		20211130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		211458280

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d205347d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:meip="http://www.meipharma.com/20211130" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-11-30_to_2021-11-30">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-11-30_to_2021-11-30">0001262104</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="meip-20211130.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-11-30_to_2021-11-30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-30</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-11-30_to_2021-11-30">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt:datemonthdayyearen">November 30, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-11-30_to_2021-11-30">MEI Pharma, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-11-30_to_2021-11-30">000-50484</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-11-30_to_2021-11-30">51-0407811</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-11-30_to_2021-11-30">11455 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-11-30_to_2021-11-30">Suite 250</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-11-30_to_2021-11-30">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-11-30_to_2021-11-30">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices) (Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-11-30_to_2021-11-30">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-11-30_to_2021-11-30">369-7100</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-11-30_to_2021-11-30">Common stock, $0.00000002 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-11-30_to_2021-11-30">MEIP</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-11-30_to_2021-11-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Emerging growth company</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#9744;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;30, 2021, MEI Pharma, Inc. (the &#8220;Company&#8221;) and Kyowa Kirin Co., Ltd issued a press release announcing the results of the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1<br /></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><a href="d205347dex991.htm">Press Release dated November&#160;30, 2021</a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">MEI PHARMA, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: November&#160;30, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Daniel P. Gold</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d205347dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g205347g1130045209186.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g205347g1130045209468.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib
as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Zandelisib Demonstrated 70.3% Objective
Response Rate; 35.2% Achieved Complete Response &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150;9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse
Event &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; MEI to Host Webcast Today at 8:00am Eastern Time &#150; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN DIEGO and TOKYO, November&nbsp;30, 2021 &#150; MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for
cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the pivotal Phase 2 TIDAL study<B>
</B>evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in
the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. The data are currently insufficiently mature to accurately estimate duration of response (DOR). In line with previously reported data from the Phase
1B study, zandelisib was generally well tolerated. With 9.4 months&nbsp;(range: <FONT STYLE="white-space:nowrap">0.8-24)</FONT> median duration of <FONT STYLE="white-space:nowrap">follow-up</FONT> in the total study population (n=121),&nbsp;interim
data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%. Patients enrolled in the study will continue to be followed for safety and DOR. Zandelisib is an investigational selective phosphatidylinositol <FONT
STYLE="white-space:nowrap">3-kinase</FONT> delta (&#147;PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&#148;) inhibitor in clinical development for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Preliminary TIDAL Data in Relapsed or Refractory (r/r) FL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing TIDAL study (NCT03768505) is a global, open-label Phase 2 trial evaluating zandelisib as a single agent across two disease cohorts: the first
cohort for the treatment of adults with r/r FL and the second cohort for r/r marginal zone lymphoma (MZL), in both cases after failure of at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody. Enrollment in the FL
cohort is complete; enrollment in the MZL cohort is ongoing. Subject to the results and discussion with the U.S. Food and Drug Administration (FDA), TIDAL study data from each study cohort are intended to be submitted to the FDA to support
accelerated approval marketing applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The r/r FL cohort enrolled a total of 121 patients, 91 of which were enrolled in the primary efficacy
population for the evaluation of ORR and DOR. The median age of patients with FL was 64 years old. Patients enrolled in both the FL primary efficacy and total patient populations received a median of 3 prior lines of treatment (range: <FONT
STYLE="white-space:nowrap">2-8).</FONT> Patients were administered zandelisib once daily for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles as response induction therapy, followed thereafter by once daily dosing for the first seven days
of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle, a schedule called Intermittent Dosing Therapy (IDT). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Efficacy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ORR in the 91 patients with r/r FL enrolled in the primary efficacy population was 70.3% (n=64), 95% CI=59.8, 79.5, as assessed by IRC after a minimum <FONT
STYLE="white-space:nowrap">follow-up</FONT> of 6 months; the complete response rate was 35.2%, 95% CI=25.4, 45.9. The ORR represents the primary endpoint of the TIDAL study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the data cutoff date, the data are not sufficiently mature to accurately estimate the final DOR in the FL primary efficacy population, a secondary
outcome measure of the TIDAL study. However, with a median <FONT STYLE="white-space:nowrap">follow-up</FONT> time for response of 8.4 months, the median DOR had not been reached. The data cutoff date is approximately 6 months after the last patient
in the primary efficacy population received their first dose of zandelisib. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety and Tolerability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zandelisib appeared generally well-tolerated in the total TIDAL study population through the data cutoff date. The safety observed in TIDAL was consistent with
data previously reported from the Phase 1B study (NCT02914938) evaluating zandelisib in patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies as a single agent or in combination with rituximab (Rituxan<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the data cutoff date, with a median follow up of 9.4 months&nbsp;(range: <FONT
STYLE="white-space:nowrap">0.8-24)</FONT> in the total FL study population, the incidence of Grade <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3 Adverse Events of Special Interest were: 1.7% ALT/AST elevation, 1.7% colitis, 5% diarrhea, 2.5%
mucositis, 0.8% pneumonitis, and 3.3% rash. The discontinuation rate due to any drug related adverse event in the group was 9.9%, also as of the data cutoff date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A more complete report of the TIDAL data as of the data cutoff date will be submitted for presentation at upcoming scientific congresses in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The emerging zandelisib data are very promising and indicate the potential to positively impact the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for patients with relapsed or refractory follicular lymphoma,&#148; said&nbsp;Daniel P. Gold, Ph.D., president and chief executive officer of&nbsp;MEI Pharma.&nbsp;&#147;The response data and
interim safety data reported today support our plans to continue discussions with the FDA on timing of an accelerated approval submission, and we look forward to reporting a more comprehensive review of the data at upcoming medical conferences while
continuing this trial and continuing to advance the zandelisib clinical development program in indications beyond follicular and marginal zone lymphomas with our partner, Kyowa Kirin.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by the zandelisib data reported today from the TIDAL study,&#148; said Yoshifumi Torii, PhD, Executive Officer, vice president, Head
of R&amp;D Division of Kyowa Kirin. &#147;Our team is continuing to study this investigational medicine with our partner MEI Pharma in the hopes of understanding zandelisib&#146;s value and bringing more hope to lymphoma patients around the
world.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEI Pharma Conference Call and Webcast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI will host an investor and analyst webcast event today, November&nbsp;30, 2021, at&nbsp;8:00 AM Eastern Time&nbsp;to review the TIDAL phase 2 study data
reported today and to provide a corporate overview. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can access the live webcast with slides under the investor relations section of MEI&#146;s website on
the &#147;Events and Presentation&#148; page at:&nbsp;<U>www.meipharma.com</U>. A replay of the webcast will be archived for at least 30 days after the conclusion of the live event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To view additional media and investor resources&nbsp;from MEI Pharma <U>click here</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zandelisib </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zandelisib, a selective PI3K<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with <FONT STYLE="white-space:nowrap">B-cell&nbsp;malignancies.</FONT> Clinical trials are
investigating the efficacy and safety of zandelisib utilizing an Intermittent Dosing Regimen (IDT), as a single agent and in combination with other modalities for the treatment of patients with <FONT STYLE="white-space:nowrap">B-cell</FONT>
malignances. The IDT leverages molecular and biologic properties specific to zandelisib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;March 2020&nbsp;the FDA granted zandelisib Fast Track
designation for treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies. In November 2021 the FDA granted zandelisib Orphan Drug designation for the treatment of patients with
follicular lymphoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020,&nbsp;MEI and Kyowa Kirin entered a&nbsp;global license, development, and commercialization agreement to further
develop and commercialize zandelisib. MEI and Kyowa Kirin will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Kyowa
Kirin has exclusive commercialization rights outside of the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ongoing zandelisib studies include the cohort in TIDAL evaluating patients with r/r
marginal zone lymphoma and continuing follow up in the cohort of the study evaluating patients with r/r follicular lymphoma. Also ongoing is the Phase 3 COASTAL study (NCT04745832) comparing zandelisib plus rituximab to standard of care chemotherapy
plus rituximab, in patients with r/r follicular or marginal zone lymphomas who received <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1 prior line of therapy, which must have included an anti-CD20 antibody in combination with chemotherapy or
lenalidomide. COASTAL is intended to support marketing applications in the&nbsp;U.S.&nbsp;and globally. Pending FDA agreement, COASTAL is also intended to act as the required confirmatory study for potential&nbsp;U.S.&nbsp;accelerated approvals of
zandelisib based on the TIDAL study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other ongoing studies include a Phase 2 pivotal study in Japan (NCT04533581) in patients with&nbsp;indolent <FONT
STYLE="white-space:nowrap">B-cell</FONT> <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma (iNHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma&nbsp;(LPL), and Waldenstr&ouml;m&#146;s macroglobulinemia (WM)
conducted by Kyowa Kirin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the TIDAL Phase 2 Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TIDAL study (<B>T</B>rials of P<B>I</B>3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><B>&nbsp;D</B>elt<B>A</B>&nbsp;in
<FONT STYLE="white-space:nowrap">Non-Hodgkin&#146;s</FONT><B>&nbsp;L</B>ymphoma) is a global Phase 2 trial evaluating zandelisib as a single agent across two study cohorts: the first cohort for the treatment of adults with r/r FL and the second
cohort for r/r MZL, in both cases after failure of at least two prior systemic therapies including chemotherapy with an alkylating agent and an anti-CD20 antibody. Subject to the results and discussions with the FDA, data from each study cohort are
intended to be submitted to the FDA to support separate accelerated approval marketing applications under 21&nbsp;CFR Part&nbsp;314.500, Subpart&nbsp;H. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study is evaluating zandelisib administered once daily at 60 mg for two
<FONT STYLE="white-space:nowrap">28-day</FONT> cycles as response induction therapy, followed thereafter by Intermittent Dosing Therapy, or &#147;IDT.&#148; The zandelisib IDT consists of once daily dosing for the first seven days of each subsequent
<FONT STYLE="white-space:nowrap">28-day</FONT> cycle and was developed based on zandelisib-specific preclinical and clinical supporting evidence. The primary efficacy endpoint is the rate of objective responses to therapy and other endpoints will
include duration of response and tolerability of zandelisib. The primary efficacy population sample size for r/r FL is 91 patients and the primary efficacy population sample size for r/r MZL is 64 patients. Complete enrollment of the FL primary
efficacy population was announced in April 2021. The total study population in the FL cohort is 121 patients to provide additional safety data for the registration application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information about this trial is available at&nbsp;<U>ClinicalTrials.gov</U> (NCT03768505). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PI3K Delta </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phosphatidylinositol <FONT
STYLE="white-space:nowrap">3-kinase</FONT> delta (PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>) is often overexpressed in cancer cells and plays a key role in the proliferation and survival of hematologic cancers. Targeting the inhibition PI3K<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> is a validated strategy in various B cell malignancies, including follicular and marginal zone lymphomas. However, PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibition can lead to immune
dysregulation, including inhibition of regulatory <FONT STYLE="white-space:nowrap">T-cell</FONT> (T-reg) activity, which is understood to contribute to immune-mediated treatment-limiting toxicities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strategies to minimize immune dysregulation, while maintaining tumor control with PI3K inhibitors, are required. Subject to suitable pharmacodynamic
characteristics, intermittent dosing of PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors is a promising approach to decouple the inhibitory activity on malignant <FONT STYLE="white-space:nowrap">B-cells</FONT> from T-reg inhibition,
potentially allowing T-reg recovery, improving tolerability and optimizing the therapeutic potential of this class of therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Follicular
Lymphoma </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Follicular lymphoma (FL) is the most common indolent lymphoma, comprising about <FONT STYLE="white-space:nowrap">20-30%</FONT> of all <FONT
STYLE="white-space:nowrap">non-Hodgkin</FONT> lymphomas (NHL). The disease also forms on <FONT STYLE="white-space:nowrap">B-cells,</FONT> is chronic in most cases and tends to progress slowly. Follicular lymphoma is most common in the elderly,
having a median age at diagnosis of approximately 65 years old. Sometimes follicular lymphomas can transform into a more aggressive form of large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma, a fast-growing type of NHL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MEI Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. (NASDAQ: MEIP) is a
late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma&#146;s portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may
support marketing approvals with the&nbsp;U.S.&nbsp;Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma&#146;s pipeline candidates leverages a different mechanism of action with the objective of developing
therapeutic options that are: (1)&nbsp;differentiated, (2) address unmet medical needs and (3)&nbsp;deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please
visit&nbsp;<U>www.meipharma.com</U>. Follow us on Twitter&nbsp;<U>@MEI_Pharma</U>&nbsp;and on&nbsp;<U>LinkedIn</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kyowa Kirin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than <FONT
STYLE="white-space:nowrap">70-year</FONT> heritage, the company applies cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including
Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions &#150; Japan, Asia Pacific, North America and EMEA/International &#150; we focus on our purpose, to make people smile, and are united by our shared values of commitment
to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: <U>https://www.kyowakirin.com</U>. Follow us on Twitter <U>@KyowaKirin_US</U> and on <U>LinkedIn</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B><I>&nbsp;</I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Under
U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are
&#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in
the forward-looking statements, which are based on management&#146;s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs
and delays in the development and or FDA approval, the availability or appropriateness of utilizing the FDA&#146;s accelerated approval pathway for our product candidates, or the failure to obtain such approval, of our product candidates;
uncertainties or differences in interpretation in clinical trial results; the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our industry and individual companies, including on our counterparties, the supply chain, the
execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and <FONT STYLE="white-space:nowrap">one-time</FONT> events. You should further be aware that with exception of the ORR data
reported in the primary follicular lymphoma efficacy population of 91 patients, the data reported today provides an initial look at the data as of the data cutoff date and is interim and subject to change as more patient data become available with
longer follow up. Because the data reported today is from an ongoing study, the final data may differ materially from the data reported in this press release. We do not intend to update any of these factors or to publicly announce the results of any
revisions to these forward-looking statements. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEI Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David A. Walsey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-369-7104</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor@meipharma.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason I. Spark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canale Communications for MEI </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">619-849-6005</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jason.spark@canalecomm.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kyowa Kirin Co., Ltd.: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hiroki Nakamura </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@kyowakirin.com
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lauren Walrath </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Public Affairs - Kyowa Kirin North
America </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">publicaffairs.na@kyowakirin.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>meip-20211130.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/30/2021 4:54:01 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:meip="http://www.meipharma.com/20211130"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.meipharma.com/20211130"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20211130_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20211130_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>meip-20211130_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/30/2021 4:54:01 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>meip-20211130_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/30/2021 4:54:01 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="meip-20211130.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g205347g1130045209186.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g205347g1130045209186.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 , # 2(  A$! Q$!_\0
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ME_VG!UQNS\F?][I^M:CSPQJC/*BJY"H2P^8GH!6.WB7P^83"M[#-'C9LA0R
MCI@!0:YUEDU#PCIT$)EMU;4UB4.I5XX_-QC'4''3TH ZU=>TIKJ2V6_@:6($
MR -D)CKD] :9=>(]'LKDV]QJ$*2K]Y<YV?[Q'3\:J>)+1+7P;>6MBB0*D.V(
M*O"^E:UC8PV%DEM$HV@?,2.78]6/J2: ([S5M/L+>.>ZO(8XY/\ 5DMG?_N@
M=?PIUAJECJ:,]E<QS!#APIY7ZCJ/QK$\+Z7#:WNJS#YVCNVA@! Q#%A6V+Z#
M<Q/Y>@JY?J(O$^D3( LDPE@D('WDV%@#]"H_7UH NW^KZ?IFT7MW%"S_ '4)
MRS?11R:+#5K#5%<V5U'-L^^JGYE],CJ*S(KG2=#O;N34-2M1?W,I9MSC>$_@
M4#K@#]23WJI+J]C?>*]%:P\R21FFBEF6)E39Y;-M+$ 'YE! YZ&@"76?#1N3
M*]M''-%*QD>W=MA5SU9&P<$]P1@UGZ9X5GMYPZVGD,#D2W$RR;/=548)^I_"
MNVHKFGA:<I<S1'(KW*\4=OIUF$+A(DZO(W4]R2>Y-<GX1\4:)J&M>(K6VU*U
M>9-0.%$J_.-BC*^HR",CTK9\7?\ (MW7U7_T(5Q,O^LT_P#ZZI_,5T))*R+.
M6OO -Y:?'R/^SR\.F:E&UU.4'!CS^\0^Q;''H:Z/X^7EI'\.6M/M$(F-U&%B
MWC=@ ]NM>H_\O$?^X?Z5P]]_R.%[]!_(4P(?@WJ5B_PRTN-;N R0HPD7S!E"
M&/4=J\OO=4L$_:8CO'O(!;+.%,V\; =F.O3KQ7H\_P#Q^7W_ %ZM_,46G_(-
M'^[0!T?BGX@>'O#&DSW5QJEH\ZH3#;QRJSR-V 4'./>N.^)6I&;X)DZA<Q"_
MN(HG:-G&XDG/ JM/_P ?*?[P_G70ZU_R-*_]<$_E0!5^!EW;-\-+*W6XB,RR
M2;HPXW#GTZUW'AS_ ) <'U;_ -"-<EHG_(X1?[C?RKN;#_CS3\?YT 6:Q[S_
M )&;3?\ KG+_ "K8JK+_ ,A&W_W6H M5P]L8!)IIO_+^P"ZGYDQL$NX[<YX^
MF>]=Q6#J/_(K7_\ NR?SH T+_5K+3+;S)YD!/$<:G+2'L% Y)^E<GIMPTVAZ
M?Y^Q+G^U@98E8$QDRD@'WQBN3^%?_(R7'^ZU=[;_ /(S:E_UV@H TO$__(N7
MG^Y6O574?^/";Z5:H Q]!_UNK?\ 7^W_ * E-U;_ )#VB8Z^;-C_ +]/5^R^
M]=?]=S_(47/_ !_67^\W_H)H S/"SV:Z.H1D6[!)O=Q D\[/S;^^<^O;&.,5
M0U'6H+GQ7HB6\D;V=O/*)[K</+$AA<+&&Z%NN?3CN:X;XK?\C+;?[J_UKM+[
.._DF]O_USB_\ 0A0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g205347g1130045209468.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g205347g1130045209468.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H +D# 2(  A$! Q$!_\0
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M&?F32LFH[8V<LJ^7T!/%<\L#75/W8ZN]_31HZX9EAG5]Z6BLUH][-,Z_P_\
M\B[IO_7M'_Z"*TJK:?:_8=.MK3=O\F)8]V.N!BK->]334$F?,U&G-M=PHHHJ
MR#-NM TB]D,EQI]N[GJVW!/Y5)9:/ING,6L[.&%CU95Y_.BBH]G"_-97-'5J
M./+S.WJ7J***LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d205347d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meip-20211130.xsd" xlink:type="simple"/>
    <context id="duration_2021-11-30_to_2021-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001262104</identifier>
        </entity>
        <period>
            <startDate>2021-11-30</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-11-30_to_2021-11-30">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-11-30_to_2021-11-30"
      id="Hidden_dei_EntityCentralIndexKey">0001262104</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-11-30_to_2021-11-30">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-11-30_to_2021-11-30">2021-11-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-11-30_to_2021-11-30">MEI Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-11-30_to_2021-11-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-11-30_to_2021-11-30">000-50484</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-11-30_to_2021-11-30">51-0407811</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-11-30_to_2021-11-30">11455 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-11-30_to_2021-11-30">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-11-30_to_2021-11-30">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-11-30_to_2021-11-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-11-30_to_2021-11-30">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-11-30_to_2021-11-30">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-11-30_to_2021-11-30">369-7100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-11-30_to_2021-11-30">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-11-30_to_2021-11-30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-11-30_to_2021-11-30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-11-30_to_2021-11-30">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-11-30_to_2021-11-30">Common stock, $0.00000002 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-11-30_to_2021-11-30">MEIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-11-30_to_2021-11-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-11-30_to_2021-11-30">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140406708132184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001262104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEI Pharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0407811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11455 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">369-7100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.00000002 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEIP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MP/<;I<S;C3T2E[]HC/X#4$L#!!0    ( +LY?E.?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( +LY?E,'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ NSE^
M4^;S+(_M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ NSE^4YE<G",0!@  G"<  !,              ( !
MRP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "[.7Y3E4AVB$@$
M  #=$   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ NSE^4Y^@&_"Q @  X@P   T              ( !
MB@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "[.7Y3EXJ[',     3 @
M"P              @ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " "[.7Y3
M'#AEZC\!   \ @  #P              @ %/$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ NSE^4R0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ NSE^4V60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d205347d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d205347d8k.htm">d205347d8k.htm</File>
    <File>d205347dex991.htm</File>
    <File>meip-20211130.xsd</File>
    <File>meip-20211130_lab.xml</File>
    <File>meip-20211130_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d205347d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d205347d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "meip-20211130_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meip-20211130_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "meip-20211130.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "meip",
   "nsuri": "http://www.meipharma.com/20211130",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d205347d8k.htm",
      "contextRef": "duration_2021-11-30_to_2021-11-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d205347d8k.htm",
      "contextRef": "duration_2021-11-30_to_2021-11-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211130/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-342891-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-342891-xbrl.zip
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M ?4(&S G"ODC)G[ 8#"U1_* /8+HVYN;>8;=V# [O)-\U3@A]]N[8]LZ.E&
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M-+Z$(]OP773N&6D/B:/7)Z#'KZ YF-X4-K,HP!4!-$. @(,^D <I^F$78X0
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MC?.4]#5=ZD>G/E%J?IQFV2P]W-PD<+RAGV^XG/@@.M)]/_-8/-2_OEQQ'LO
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MN8YZ!^XT#@%W\_5XY(;9?ERWVV>L[V.VV\C=SK#AVZUVX-#K?U!+ P04
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M6MFT9L,P ,_PTN8 C)H.P.C%#<#(=@!&;0S Z/L-P'3-6QL )!O6 U#I!7T
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M*N[FB/DP+Y9BR5]02P$"% ,4    " "[.7Y3A\+<%&P.  #18@  #@
M        @ $     9#(P-3,T-V0X:RYH=&U02P$"% ,4    " "[.7Y3$E"P
M@(8=   B:0  $0              @ &8#@  9#(P-3,T-V1E>#DY,2YH=&U0
M2P$"% ,4    " "[.7Y36),KV4P#  !^"P  $0              @ %-+
M;65I<"TR,#(Q,3$S,"YX<V102P$"% ,4    " "[.7Y3M1/!#8$&  !*1P
M%0              @ '(+P  ;65I<"TR,#(Q,3$S,%]L86(N>&UL4$L! A0#
M%     @ NSE^4SU.&W[&!   TBP  !4              ( !?#8  &UE:7 M
F,C R,3$Q,S!?<')E+GAM;%!+!08     !0 % $ !  !U.P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
